- RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
For: Chronic Hepatitis DAustria · Czechia · France - Active not recruiting
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
This study looks at how a medicine called bulevirtide works over time for people with chronic hepatitis D infection. Researchers want to understand its long-term effects and make sure it's safe for patients taking it.
For: Chronic Hepatitis D InfectionAustria · France · Germany - Active not recruitingPHASE2
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
This study is testing new medicines, Tobevibart and Elebsiran, against an existing treatment, Bulevirtide. It's for people in the UK who have long-lasting hepatitis delta virus (HDV) infection to see which treatment works best to control the virus and improve liver health.
For: Viral HepatitisBelgium · Bulgaria · France - RecruitingPHASE3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This study is for people with chronic Hepatitis D (HDV) whose current medicine, bulevirtide, isn't fully controlling the virus. It will test if a new combination of medicines, tobevibart and elebsiran, works better. It's a key step in finding more effective treatments.
For: Viral HepatitisAustria · France · Germany